Back to search

Switzerland· 67669001

Vocabria 30 mg, Filmtabletten

A cabotegravir product containing cabotegravirum, registered in Switzerland by ViiV Healthcare GmbH and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 14 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC J05AJ04

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedVocabria 30 mg, FilmtablettenATCJ05AJ04REGISTER NO.67669001PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Cabotegravir is registered in 14 of 19 countries.

Countries holding a registration under ATC J05AJ04 (cabotegravir), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 9 of them publish a price we can compare per daily dose

Cabotegravir · ATC J05AJ04

14 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of cabotegravir costs, country by country.

Normalised to the WHO defined daily dose (30 mg), so markets compare like for like.

  • Switzerland: $24.58 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Cabotegravir · price per daily dose (30 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$24.58
  • FR France$20.75
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
cabotegravirum
Manufacturer
ViiV Healthcare GmbH
Country
Switzerland (CH)
ATC code
J05AJ04
ATC class
Cabotegravir
Defined daily dose
30 mg, O
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680676690014
    Fl 30 Stk
    CHF 611.45

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

13 interactions on record for cabotegravir.

Graded by severity as the source publishes them — 13 moderate. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Cabotegravir · interactions on record

13 records

  • 13 moderate

Most severe, free to view

  • Magnesium carbonateA02AA01moderate
  • Magnesium oxideA02AA02moderate
  • Magnesium hydroxideA02AA04moderate
  • Kombinationen von AluminiumsalzenA02AB10moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Cabotegravir in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All cabotegravir products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Apretude, Vocabria
  • Liechtenstein · Apretude, Vocabria
  • Norway · Apretude, Vocabria

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/de6f8e56-5549-4200-9cd9-4d40bb69eca3
GET /v1/drugs/de6f8e56-5549-4200-9cd9-4d40bb69eca3?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "cabotegravirum 30 mg",
  "valid_from": "2022-03-01",
  "limitations": "[{\"description\":\"VOCABRIA Tabletten werden nur in Kombination mit Rilpivirin Tabletten zur kurzfristigen Behandlung einer HIV-1-Infektion bei Erwachsenen vergütet, die seit mindestens 6 Monaten vor Umstellung auf die Cabotegravir-Rilpivirin-Kombination unter einer stabilen antiretroviralen Therapie virologisch supprimiert (HIV-1 RNA <50 Kopien/ml) sind und keine bekannten oder vermuteten Resistenzen gegen sowie in der Vorgeschichte kein virologisches Versagen mit Wirkstoffen aus der NNRTI- oder INI-Klasse aufweisen.<br>\\n<br>\\nVOCABRIA Tabletten werden vergütet zur oralen Einleitungsbehandlung, um vor Therapiebeginn mit langwirksamen Cabotegravir-Injektionen die Verträglichkeit von Cabotegravir in Kombination mit Rilpivirin Tabletten zu testen oder als orale Überbrückungsbehandlung für Erwachsene, die geplante Cabotegravir-Injektionen versäumen werden.<br>\\n<br>\\n\",\"costApproval\":null,\"indication\":\"\",\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2025-12-01\"}]",
  "galenic_form": "Filmtabl 30 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2022-03-01",
  "self_retention_pct": 10
}

See everything about cabotegravir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.